Last reviewed · How we verify
CHF5993 pMDI
CHF5993 pMDI is a corticosteroid inhalation powder for the maintenance treatment of asthma and the treatment of chronic obstructive pulmonary disease (COPD).
CHF5993 pMDI is a corticosteroid inhalation powder for the maintenance treatment of asthma and the treatment of chronic obstructive pulmonary disease (COPD). Used for Maintenance treatment of asthma, Treatment of chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | CHF5993 pMDI |
|---|---|
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
It works by reducing inflammation in the lungs, making it easier to breathe. CHF5993 pMDI is a dry powder inhaler that delivers a precise dose of the corticosteroid to the lungs, where it can be most effective.
Approved indications
- Maintenance treatment of asthma
- Treatment of chronic obstructive pulmonary disease (COPD)
Common side effects
- Oral thrush
- Headache
- Cough
- Sore throat
- Nausea
Key clinical trials
- A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (PHASE3)
- Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma (PHASE2)
- Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS). (PHASE3)
- Step-up to Medium Strength Triple Therapy vs High Strength ICS/LABA in Adult Asthmatics Uncontrolled on Medium Strength ICS/LABA (PHASE4)
- Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR® (PHASE1)
- A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV) (PHASE1)
- CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD (PHASE4)
- Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHF5993 pMDI CI brief — competitive landscape report
- CHF5993 pMDI updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI